Janssen Sciences Ireland UC

Intent: To signal the importance of successful outcomes to the EU pharma package to the industry in Ireland::To communicate the long-term potential for the development of the life sciences industry in Ireland

Methods: Email

Intent: To highlight the need for an increased focus on competitiveness, and to develop both Ireland and the EU's investment climate for the life sciences industry post-Draghi Report::To highlight industry concerns arising from EU policy files including the EU Pharma Package (proposed cuts to regulatory data protection), the Urban Wastewater Treatment Directive, and local medicines reimbursement challenges.::To highlight supply chain concerns for the industry on medicine shortages and the Critical Medicines Act and to highlight recommendations from the Critical Medicines Alliance.::To adopt an appropriate approach to civil justice reform at EU level, protecting Europe's legal framework through Third Party Litigation legislation.

Methods: Meeting

Intent: To promote the development and adoption by the new Government of a national life sciences strategy

Methods: Informal communication, Email, Submission

Intent: To highlight the risks associated with Third Party Litigation Funding in the context of the Products Liability Directive::To encourage EU regulation on this area and the imposition of a transparency obligation with respect to TPLF

Methods: Informal communication

Intent: To promote the policies outlined in the IPHA General Election manifesto and highlight the positive economic impact of J&J facilities on their local communities.::To speed up the reimbursement process for new medicines in line with IPHA proposals and strengthen the role of clinicians in medicines prioritisation::To develop a national life sciences strategy

Methods: Informal communication, Email, Submission

Intent: To ensure sufficient funding in Budget 2025 to ensure patient access to newly authorised medicines.

Methods: Email

Intent: To ensure implementation of the Medicines Reimbursement Tracker by the Dept. of Health and finalisation of other reforms suggested by the Mazars Working Group.

Methods: Informal communication

Intent: To improve patient access to new medicines by modernising and speeding up the reimbursement process in line with IPHA proposals.::To ensure a stable budget for new medicines reimbursements in the coming years.::To protect existing levels of Regulatory Data Protection for innovative medicines at European level.

Methods: Meeting, Email, Submission

Intent: To protect existing levels of Regulatory Data Protection for innovative medicines in Europe.

Methods: Informal communication

Intent: To promote completion of the 'Mazars process' of reviewing and recommending reforms to the reimbursement system for new medicines in Ireland.::To promote publication of the report of the Dept. of Health Mazars Implementation Working Group and implementation of its recommendations.

Methods: Email